JP2016513647A - レプチン生産を増進するビマトプロスト - Google Patents

レプチン生産を増進するビマトプロスト Download PDF

Info

Publication number
JP2016513647A
JP2016513647A JP2016502054A JP2016502054A JP2016513647A JP 2016513647 A JP2016513647 A JP 2016513647A JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016513647 A JP2016513647 A JP 2016513647A
Authority
JP
Japan
Prior art keywords
bimatoprost
administered
leptin
human
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513647A5 (enExample
Inventor
ニール ジェイ ポロソ
ニール ジェイ ポロソ
バーク　ロバート　エム
ロバート エム バーク
ガースト　マイケル　イー
マイケル イー ガースト
ディヴィッド エフ ウッドワード
ディヴィッド エフ ウッドワード
ティモシー ジェイ マツィアス
ティモシー ジェイ マツィアス
スザンヌ カナリー
スザンヌ カナリー
グラントリー チャールズ
グラントリー チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016513647A publication Critical patent/JP2016513647A/ja
Publication of JP2016513647A5 publication Critical patent/JP2016513647A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016502054A 2013-03-15 2014-03-13 レプチン生産を増進するビマトプロスト Pending JP2016513647A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
US61/793,132 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (2)

Publication Number Publication Date
JP2016513647A true JP2016513647A (ja) 2016-05-16
JP2016513647A5 JP2016513647A5 (enExample) 2017-04-13

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502054A Pending JP2016513647A (ja) 2013-03-15 2014-03-13 レプチン生産を増進するビマトプロスト

Country Status (11)

Country Link
US (2) US20140275272A1 (enExample)
EP (1) EP2968361A1 (enExample)
JP (1) JP2016513647A (enExample)
KR (1) KR20150129735A (enExample)
CN (1) CN105338985A (enExample)
AU (1) AU2014228307A1 (enExample)
BR (1) BR112015021859A2 (enExample)
CA (1) CA2901529A1 (enExample)
HK (1) HK1220385A1 (enExample)
RU (1) RU2015134772A (enExample)
WO (1) WO2014143629A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983942A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
JP2012516187A (ja) * 2009-02-20 2012-07-19 マイクロ ラブズ リミテッド 貯蔵安定性プロスタグランジン製品
WO2012099942A2 (en) * 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
JP2012516187A (ja) * 2009-02-20 2012-07-19 マイクロ ラブズ リミテッド 貯蔵安定性プロスタグランジン製品
WO2012099942A2 (en) * 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome

Also Published As

Publication number Publication date
US20160310505A1 (en) 2016-10-27
KR20150129735A (ko) 2015-11-20
US20140275272A1 (en) 2014-09-18
EP2968361A1 (en) 2016-01-20
RU2015134772A (ru) 2017-04-21
RU2015134772A3 (enExample) 2018-03-21
CA2901529A1 (en) 2014-09-18
HK1220385A1 (zh) 2017-05-05
CN105338985A (zh) 2016-02-17
BR112015021859A2 (pt) 2017-07-18
WO2014143629A1 (en) 2014-09-18
AU2014228307A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
JP7590803B2 (ja) 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
AU782515B2 (en) Pharmaceutical and cosmetic carrier or composition for topical application
US8512718B2 (en) Pharmaceutical composition for topical application
KR101954869B1 (ko) 탈모증 치료제
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
EP3684411A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
JP2016513647A (ja) レプチン生産を増進するビマトプロスト
CN1972661B (zh) 呋喃烷基用于蜂窝组织化妆处理的用途
WO2016014680A2 (en) Oral transmucosal compositions including aromatase inhibitors for low testoterone levels in men
JP5777156B2 (ja) 慢性痒疹治療用外用剤
Saisakphong et al. Effect of Vitamin C on postoperative pain after dental implant surgery
JP5023323B2 (ja) アクアポリン５の発現亢進剤
TW202131927A (zh) 睾固酮組合物
HK1174049A (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
EA028400B1 (ru) Способ профилактики и лечения ожирения и избыточного веса и связанных с ними нарушений
TW200934476A (en) Composition and method for the treatment of gynoid lipodystrophy (cellulite)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180723